German Lawmakers Reject Medical Cannabis Insurance Coverage Expansion

Committee Vote Blocks Coverage Expansion

The Bundestag Health Committee rejected the medical cannabis insurance expansion proposal in a committee vote held July 10, 2026. The measure, introduced by opposition lawmakers, sought to ease statutory health insurance (gesetzliche Krankenversicherung, or GKV) reimbursement criteria for cannabis prescriptions. Current coverage rules remain unchanged, requiring patients to meet narrow approval thresholds before insurers reimburse cannabis therapy costs.

The vote follows months of advocacy by patient groups and industry stakeholders who said Germany's existing reimbursement framework—in place since the 2017 Cannabis as Medicine Act—creates financial and administrative barriers. Under current law, GKV insurers must approve coverage only when standard treatments have failed and a physician attests that cannabis offers a reasonable prospect of benefit. Rejection rates for initial applications routinely exceed 30 percent, according to data from the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, or BfArM).

Committee vote details weren't recorded, but coalition party members from the SPD and Greens reportedly joined CDU/CSU lawmakers in opposing the measure. No floor vote is scheduled.

Current Coverage Rules and Patient Impact

Germany's statutory health insurance system covers medical cannabis only after prior authorization, a process that denies roughly one-third of initial requests and imposes delays averaging four to six weeks. When insurers deny coverage, patients either abandon cannabis therapy or pay out-of-pocket costs that range from €300 to €800 per month, depending on dosage and product selection.

For full background on Germany's medical cannabis framework, see the CannIntel topic hub on Germany Medical Cannabis.

Key coverage barriers under the status quo include:

• Mandatory documentation that conventional therapies (opioids, anticonvulsants, chemotherapy adjuncts) failed or caused intolerable side effects.
• Physician attestation that cannabis offers a "not entirely remote" prospect of meaningful benefit—a vague standard that insurers interpret inconsistently.
• No automatic approval for any diagnosis; each case requires individual review.
• High rejection rates for chronic pain indications (35–40 percent) compared to oncology and palliative cases (15–20 percent).

The rejected proposal would have created a positive list of qualifying conditions—including multiple sclerosis, chemotherapy-induced nausea, chronic pain syndromes, and epilepsy—that would trigger automatic coverage without prior authorization. It also sought to cap insurer response times at two weeks and establish an appeals pathway through regional social courts.

Industry and Advocacy Response

Patient advocacy organizations and domestic cannabis producers criticized the committee's decision. They warn it perpetuates a two-tier system where wealthier patients access therapy while lower-income patients face denials. The German Cannabis Industry Association (Deutscher Hanfverband, or DHV) issued a statement calling the vote "a missed opportunity to align policy with clinical evidence and patient need."

The committee's refusal to modernize coverage rules leaves tens of thousands of patients in a bureaucratic maze that delays or denies access to a legal medicine, forcing many to choose between financial hardship and untreated symptoms.

Germany's medical cannabis market has grown steadily since 2017 legalization, with approximately 300,000 active patients and annual sales approaching €500 million. Growth has plateaued in recent quarters. Reimbursement friction and the April 2024 launch of adult-use cannabis social clubs (Anbauvereinigungen) have shifted some demand outside the medical channel.

Domestic cultivators, including Demecan and Aphria Deutschland, have lobbied for expanded coverage to stabilize medical demand and justify continued investment in GMP-certified production infrastructure. The committee vote is a setback for those efforts.

What Comes Next

With no floor vote scheduled and coalition support absent, the rejected proposal is effectively dead for the remainder of the current Bundestag session, which runs through September 2027. Advocates may attempt to reintroduce similar language in 2027 or attach coverage reforms to broader health-system legislation, but near-term prospects are limited.

The Federal Ministry of Health (Bundesministerium für Gesundheit, or BMG) hasn't signaled interest in administrative rule changes that could ease coverage without legislative action. Ministry officials have historically deferred to the Bundestag on reimbursement policy, and current Health Minister Karl Lauterbach hasn't prioritized cannabis access in recent public statements.

Patient advocates are now focusing on regional strategies, including litigation in social courts to challenge individual denials and lobbying state-level health ministers to issue guidance encouraging more liberal approval standards. Early results are mixed. Courts in North Rhine-Westphalia and Bavaria have issued contradictory rulings on what constitutes adequate documentation of prior treatment failure.

The next legislative window for coverage reform may not open until after the 2027 federal election, leaving the current restrictive framework in place for at least 14 more months. We'll be watching whether regional court rulings create pressure for federal action and whether patient enrollment stagnation forces coalition reconsideration before the election cycle.